title: A validated RP-HPLC method for simultaneous determination of propranolol and valsartan in bulk drug and gel formulation.
abstract: OBJECTIVE
  A simple, precise, and stability indicating high performance liquid chromatography (HPLC) method was developed and validated for the simultaneous determination of propranolol hydrochloride and valsartan in pharmaceutical dosage form.
  
  
  METHODS
  The method involves the use of easily available inexpensive laboratory reagents. The separation was achieved on Hypersil ODS C-18 column (250*4.6 mm, i.d., 5 μm particle size) with isocratic flow with UV detector. The mobile phase at a flow rate of 1.0 mL/min consisted of acetonitrile, methanol, and 0.01 M disodium hydrogen phosphate (pH 3.5) in the ratio of 50:35:15 v/v.
  
  
  RESULTS
  A linear response was observed over the concentration range 5-50 μg/mL of propranolol and the concentration range 4-32 μg/mL of valsartan. Limit of detection and limit of quantitation for propranolol were 0.27 μg/mL and 0.85 μg/mL, and for valsartan were 0.45 μg/mL and 1.39 μg/mL, respectively. The method was successfully validated in accordance to ICH guidelines acceptance criteria for linearity, accuracy, precision, specificity, robustness.
  
  
  CONCLUSIONS
  The analysis concluded that the method was selective for simultaneous estimation of propranolol and valsartan can be potentially used for the estimation of these drugs in combined dosage form.
authors.affiliation: Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, New Delhi, India.
authors.forename: Syed Sarim
authors.initials: SS
authors.lastname: Imam
authors.forename: Abdul
authors.initials: A
authors.lastname: Ahad
authors.forename: Mohammed
authors.initials: M
authors.lastname: Aqil
authors.forename: Yasmin
authors.initials: Y
authors.lastname: Sultana
authors.forename: Asgar
authors.initials: A
authors.lastname: Ali
keywords: Propanalol; RP-HPLC; valsartan
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2002 May 25;772(1):81-7
references.pmid: 12016018
references.citation: Arch Intern Med. 1995 Jul 10;155(13):1361-8
references.pmid: 7794084
references.citation: J Pharm Biomed Anal. 2001 Jul;25(5-6):1009-13
references.pmid: 11377086
references.citation: J Hypertens. 2001 Sep;19(9):1691-6
references.pmid: 11564991
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 25;766(2):345-9
references.pmid: 11824822
references.citation: Drug Dev Ind Pharm. 2001 Aug;27(7):693-7
references.pmid: 11694017
references.citation: J Chromatogr A. 2002 Mar 8;949(1-2):49-60
references.pmid: 11999756
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):436-42
references.pmid: 17331816
references.citation: Farmaco. 2003 Nov;58(11):1179-86
references.pmid: 14572869
references.citation: J Pharm Biomed Anal. 2002 Sep 5;30(2):371-5
references.pmid: 12191724
references.citation: Circulation. 2001 Jan 2;103(1):148-54
references.pmid: 11136700
references.citation: Farmaco. 2000 Feb;55(2):136-45
references.pmid: 10782386
references.citation: J Chromatogr A. 2002 Jul 26;964(1-2):179-87
references.pmid: 12198846